Merck & Company Inc. Common Stock (new) (MRK)
MRK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$141.98
-2.39% on the day
Market cap
$350.3B
Mega cap
Revenue · 2025
$65.0B
+1.3% on 2024
Net income · 2025
$18.3B
28.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MRK on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000310158 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NJ |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $65.0B |
| Net income | $18.3B |
| Operating income | Not in SEC XBRL data |
| Net margin | 28.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +1.3% |
| Cash | $14.6B |
| Total assets | $136.9B |
| P/E (computed) | 19.2× |
| P/S (computed) | 5.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-20 |
| Latest annual report 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025 | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-08-07 |
| Latest current report | 8-K | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-04-08 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.2% |
| 1 month | +2.5% |
| 3 months | +15.5% |
| Year to date | +40.0% |
| 1 year | +72.0% |
| From 52-week high | -5.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVS | Novartis AG | $142.41 | -0.99% | $271.7B |
| ABBV | AbbVie Inc. | $274.36 | -2.40% | $484.8B |
| AZN | AstraZeneca PLC | $155.82 | -1.58% | $241.6B |
| JNJ | Johnson & Johnson | $248.61 | -5.73% | $599.1B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier